Tectonic Therapeutic
127 Western Ave
Allston
Massachusetts
02134
United States
Website: http://tectonictx.com/
Email: info@tectonictx.com
13 articles about Tectonic Therapeutic
-
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
3/26/2024
Tectonic Therapeutic, Inc., a privately-held biotechnology company developing GPCR -targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fusion molecule.
-
Tectonic Therapeutic Announces Participation at Investor Conferences in March
2/27/2024
Tectonic Therapeutic, Inc. today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March.
-
AVROBIO and Tectonic Therapeutic Announce Merger
1/30/2024
AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).
-
Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic
11/28/2023
Tectonic Therapeutic, Inc. today announced it completed dosing of the first human cohort in its Fc-relaxin fusion program targeting the RXFP1 receptor.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers.
-
Tectonic Therapeutic Strengthens Leadership Team
7/19/2022
Tectonic Therapeutic , Inc. today announced the promotion of Senior Vice President, Head of Research, Peter McNamara, PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves as Vice President, Biologics Manufacturing.
-
Fierce Biotech Names Tectonic Therapeutic as One of Its “Fierce 15” Biotech Companies of 2021
9/27/2021
Tectonic Therapeutic today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
-
BioSpace Movers & Shakers, July 23
7/23/2021
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Tectonic Therapeutic Appoints Marcella Ruddy, MD as Chief Medical Officer
7/22/2021
Tectonic Therapeutic today announced that Dr. Marcella (“Marcie”) Ruddy, MD has been appointed Chief Medical Officer.
-
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
-
BioSpace Movers & Shakers, May 28
5/28/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Tectonic Therapeutic Appoints Peter McNamara, PhD Senior Vice President, Head of Research
5/27/2021
Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.
-
Tectonic Therapeutic Launches with $80 Million Series A Financing to Transform the Discovery of Novel G-Protein Coupled Receptor (GPCR)-Targeted Therapies
4/15/2021
Series A financing co-led by Vida Ventures, T.A. Springer, and Polaris Partners with participation from EcoR1 Capital Tectonic’s proprietary technology platform based on pioneering work from the Harvard lab of co-founder, Andrew Kruse, PhD Industry veteran Alise Reicin, MD named President and Chief Executive Officer